Viatris CEO Talks Integration, Roadmap And Interchangeable Biosimilars
Michael Goettler Sets Out Vision For Viatris On Anniversary Of Mylan-Upjohn Merger
As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.
